Advertisement

Ads Placeholder
Loading...

MDxHealth SA

MXDHFPNK
Healthcare
Medical - Diagnostics & Research
$0.25
$-0.03(-9.09%)
U.S. Market opens in 57h 54m

MDxHealth SA Fundamental Analysis

MDxHealth SA (MXDHF) shows weak financial fundamentals with a PE ratio of -3.22, profit margin of -31.07%, and ROE of 5.17%. The company generates $0.1B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position232.13%
PEG Ratio-0.16

Areas of Concern

ROE5.17%
Operating Margin-14.28%
We analyze MXDHF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 106.9/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.

Fundamental Health Score

A
106.9/100

We analyze MXDHF's fundamental strength across five key dimensions:

Efficiency Score

Weak

MXDHF struggles to generate sufficient returns from assets.

ROA > 10%
-22.66%

Valuation Score

Excellent

MXDHF trades at attractive valuation levels.

PE < 25
-3.22
PEG Ratio < 2
-0.16

Growth Score

Weak

MXDHF faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

MXDHF maintains a strong and stable balance sheet.

Debt/Equity < 1
-7.86
Current Ratio > 1
1.08

Profitability Score

Weak

MXDHF struggles to sustain strong margins.

ROE > 15%
5.17%
Net Margin ≥ 15%
-31.07%
Positive Free Cash Flow
No

Key Financial Metrics

Is MXDHF Expensive or Cheap?

P/E Ratio

MXDHF trades at -3.22 times earnings. This suggests potential undervaluation.

-3.22

PEG Ratio

When adjusting for growth, MXDHF's PEG of -0.16 indicates potential undervaluation.

-0.16

Price to Book

The market values MDxHealth SA at -8.94 times its book value. This may indicate undervaluation.

-8.94

EV/EBITDA

Enterprise value stands at -7.24 times EBITDA. This is generally considered low.

-7.24

How Well Does MXDHF Make Money?

Net Profit Margin

For every $100 in sales, MDxHealth SA keeps $-31.07 as profit after all expenses.

-31.07%

Operating Margin

Core operations generate -14.28 in profit for every $100 in revenue, before interest and taxes.

-14.28%

ROE

Management delivers $5.17 in profit for every $100 of shareholder equity.

5.17%

ROA

MDxHealth SA generates $-22.66 in profit for every $100 in assets, demonstrating efficient asset deployment.

-22.66%

Following the Money - Real Cash Generation

Operating Cash Flow

MDxHealth SA generates limited operating cash flow of $-7.20M, signaling weaker underlying cash strength.

$-7.20M

Free Cash Flow

MDxHealth SA generates weak or negative free cash flow of $-8.00M, restricting financial flexibility.

$-8.00M

FCF Per Share

Each share generates $-0.23 in free cash annually.

$-0.23

FCF Yield

MXDHF converts -10.43% of its market value into free cash.

-10.43%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-3.22

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.16

vs 25 benchmark

P/B Ratio

Price to book value ratio

-8.94

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.03

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-7.86

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.08

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

5.17

vs 25 benchmark

ROA

Return on assets percentage

-0.23

vs 25 benchmark

ROCE

Return on capital employed

-0.16

vs 25 benchmark

How MXDHF Stacks Against Its Sector Peers

MetricMXDHF ValueSector AveragePerformance
P/E Ratio-3.2228.45 Better (Cheaper)
ROE516.59%763.00% Weak
Net Margin-31.07%-45265.00% (disorted) Weak
Debt/Equity-7.860.34 Strong (Low Leverage)
Current Ratio1.082795.60 Neutral
ROA-22.66%-16588.00% (disorted) Weak

MXDHF outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews MDxHealth SA's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ